eyeforpharma Barcelona 2016 conference

eyeforpharma 15 - 17 March 2016, Barcelona, Spain.
eyeforpharma Barcelona will set the vision for your 2020 plans. With 120% attendee growth you can join 1000+ industry leaders in commercial excellence, patient engagement and innovation at the unmissable pharma-stakeholder summit. As your customer takes charge this meeting will enable you take the steps you need to become their partner of choice.

The conference will bring together all key stakeholders, so you can collaborate and identify solutions in order to:

  • Gain Real Customer Insight. Reinvent your understanding of customer experience with a holistic multichannel solution
  • Deliver Outcomes. Enhance patient experience by partnering with external stakeholders and facilitating internal cross functionality
  • Sell Value. Engage the busier, more informed customer with impactful face-to-face, remote and digital communication
  • Develop a New Corporate Culture. Pioneer a progressive internal mind-set promoting collaboration, communication and trust

Why Attend?
90+ industry leading speakers including C-Suite, VP and Director level experts to share their experiences so you can make healthier corporate decisions. 2016 speakers include:

Keynotes

  • David Epstein, Novartis, Division Head and CEO Pharmaceuticals
  • Dominique Limet, ViiV, Healthcare
  • Jane Griffiths, Janssen, Company Group Chairman, Europe, Middle East & Africa
  • Gitte Aabo, LEO Pharma, CEO
  • Eduardo Javier Sanchiz Yrazu, Almirall, CEO
  • Murray Stewart, GSK, Chief Medical Officer
  • Tim Kneen, Merck, Executive President, Europe & Canada
  • David Loew, Sanofi Pasteur, COO
  • Andrew Hotchkiss, Eli Lilly and Company, President Europe and Canada
  • Jason DeGoes, Teva, SVP Patient Solutions

Patient Experience

  • Kasper Jerlang, LEO Pharma, Head - Global Patient Communications
  • Sanja Njegic, Novartis, Director Patient Relations, Europe
  • Henrik Finnern, Boehringer Ingelheim, Chief Patient Office
  • Anne Beal, Sanofi, Chief Patient Officer
  • Paul Robinson, MSD, Executive Director Scientific Medical and Patient Perspective

Commercial Excellence

  • Andreas Wandelt, Pfizer, Vice President, Global Sales and Marketing Services
  • Heléna Bargiel, LEO Pharma, Head of Global Field Force Excellence
  • Etienne Tichit, Novo Nordisk, Vice President, Commercial Excellence
  • Bharat Tewarie, UCB, EVP & Chief Marketing Officer
  • Chris-Carol Bremer, Grunenthal, SVP & Head of Marketing

See the complete speaker line-up here.

Don't miss Barcelona 2016, Europe’s premier pharmaceutical summit in commercial excellence, patient engagement and innovation!

Save €100 using World Pharma News unique code wpn100

For further information, please visit:
http://www.eyeforpharma.com/barcelona/

About eyeforpharma
Our mission is to make pharma more open and valued. The ultimate driver for the pharmaceutical industry's health is meeting the needs of patients, otherwise it will cease to matter. For healthcare to be as good as it could be, the strength, skills and resources of our industry need to be fully integrated into health outcomes and we need pharma experience at the decision-making table. We believe the industry must focus on a business model combining service with product, with patients at the center.

Most Popular Now

New strategy to treat Parkinson's disease

Northwestern Medicine scientists have used patient-derived neurons to develop and test a new strategy to treat Parkinson's disease by mitigating the effects of harmful ge...

AI could offer warnings about serious side effects…

The more medications a patient takes, the greater the likelihood that interactions between those drugs could trigger negative side effects, including long-term organ dama...

OPKO and Pfizer announce positive Phase 3 top-line…

OPKO Health Inc. (NASDAQ: OPK) and Pfizer Inc. (NYSE: PFE) announced that the global Phase 3 trial evaluating somatrogon dosed once-weekly in pre-pubertal children with g...

Trastuzumab deruxtecan granted FDA Priority Review…

AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) today announced that the US Food and Drug Administration (FDA) has accepted for review the Biologics Lice...

The Bristol-Myers Squibb-Pfizer Alliance and Fitbi…

The Bristol-Myers Squibb-Pfizer Alliance and Fitbit announced at the TIME 100 Health Summit in New York that they are working together to help drive timely diagnosis of a...

Nplate® (romiplostim) now approved for earlier use…

Amgen (NASDAQ:AMGN) announced that the U.S. Food and Drug Administration (FDA) approved Amgen's Supplemental Biologics License Application (sBLA) for Nplate® (romiplostim...

Bayer launches LifeHub UK focused on artificial in…

Bayer launched LifeHub UK to accelerate and optimize disease detection and data-driven drug discovery by developing artificial-intelligence-enabled imaging solutions. The...

Novartis announces that Jakavi® (ruxolitinib) meet…

Novartis today announced positive topline results from the Phase III REACH2 study evaluating Jakavi® (ruxolitinib) in patients with steroid-refractory acute graft-versus-...

Amgen recommends rejection of 'mini-tender' offer …

Amgen (NASDAQ:AMGN) today announced that it has been notified of an unsolicited "mini-tender" offer dated Oct. 11, 2019, made by TRC Capital Corporation, a private Canadi...

Antibody-based eye drops show promise for treating…

Researchers at the University of Illinois at Chicago are the first to identify the presence of a specific type of antibody, called anti-citrullinated protein autoantibodi...

First entirely digital clinical trial encourages p…

As little as a daily ping on your phone can boost physical activity, researchers from the Stanford University School of Medicine and their collaborators report in a new s...

Abbott and Omada Health partner to offer integrate…

Abbott (NYSE: ABT) and Omada Health announced today they are partnering to integrate Abbott's revolutionary FreeStyle Libre system, a continuous glucose monitoring (CGM) ...